CZCheng Zhang

Cheng Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Cheng Zhang has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Ke Sun

    Department of Hepatobiliary and Pancreatic Surgery, Chengdu Second People’s Hospital, Affiliated Hospital of West China School of Medicine, Sichuan University, Chengdu, China

    4 shared publications
  • Yang He

    Department of Hepatobiliary Surgery, West China School of Medicine, Sichuan University affiliated Chengdu Second People’s Hospital, Chengdu, Sichuan Province, China

    3 shared publications
  • Lin Wang

    Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, China

    2 shared publications
  • Shenglong Zhang

    Department of Hepatobiliary and Pancreatic Surgery, Chengdu Second People’s Hospital, Affiliated Hospital of West China School of Medicine, Sichuan University, Chengdu, China

    2 shared publications
  • Yun-Sheng Suo

    2 shared publications
  • Guang-Kuo Li

    Department of hepatobiliary surgery, Chengdu Second People’s Hospital, Chengdu, China

    1 shared publication

Latest Publications

  • Clinical Course of Temporary Internal Biliary Stents after Laparoscopic Common Bile Duct Exploration: A Systematic Review and Meta-Analysis

    by Cheng Zhang, Shenglong Zhang, Ke Sun

    Introduction: Temporary internal biliary stents placed after laparoscopic common bile duct exploration (LCBDE) are designed to decompress the duct and pass without elective endoscopic removal, but their subsequent clinical course has not been systematically evaluated. Materials and Methods: Eight English- and Chinese-language databases were searched through July 29, 2026. Eligible studies evaluated temporary internal stents intended for spontaneous passage after LCBDE. Two reviewers independently selected studies, extracted public aggregate data, resolved overlapping cohorts, and assessed risk of bias. Single-arm outcomes were pooled using random-effects binomial-normal generalized linear mixed models. A prespecified sensitivity analysis excluded studies authored by the review team. Results: Fifteen studies included 1004 stent recipients, although outcome-specific quantitative syntheses were limited to studies with compatible reporting. Overall confirmed passage was 96.8% (350/371; 95% confidence interval [CI], 87.6%−99.2%; I 2 = 64.2%) and remained 98.1% (249/259; 95% CI, 87.7%−99.7%) after excluding review-team studies. Passage by approximately 30 days was 98.0% (147/151; 95% CI, 85.5%−99.8%); directly reported 30-day data yielded 99.2% (127/128; 95% CI, 94.7%−99.9%). Endoscopic removal or retrieval occurred in 2.6% (12/353; 95% CI, 0.7%−9.3%). Heterogeneous devices and time origins precluded pooling passage time. Conclusion: Temporary internal stents usually pass spontaneously after LCBDE, although performance varies across devices and settings. When passage has not been documented, approximately 1 month is the best-supported verification checkpoint. Persistent, migrated, or symptomatic stents warrant targeted evaluation and early endoscopic consultation. This pathway is evidence-informed rather than a formal guideline recommendation. Given the predominantly East Asian evidence base, validation in other populations is required.

  • Single-Incision Laparoscopic Common Bile Duct Exploration with a Single-Bend Internal Biliary Stent: A Consecutive Cohort Study of 112 Patients

    by Cheng Zhang, Ke Sun, Zhiqiang Yang, Yang He, Yunsheng Suo, Xianlin Cheng, Shenglong Zhang

    Introduction: Single-incision laparoscopic common bile duct exploration (SIL-CBDE) with primary duct closure is technically demanding. This study evaluated a standardized SIL-CBDE protocol using a guidewire-pusher-single-bend internal biliary stent delivery system designed to permit spontaneous dislodgement. Materials and Methods: We retrospectively analyzed 112 consecutive patients who underwent SIL-CBDE with internal biliary drainage between April 2025 and April 2026. A guidewire-pusher-stent delivery system with a 5 Fr single-bend plastic stent was used for temporary transpapillary decompression. Technical proficiency was assessed using risk-adjusted cumulative sum (RA-CUSUM) analysis adjusted for age, body mass index, common bile duct (CBD) diameter, and stone characteristics. Results: Technical success was achieved in all patients. The mean operative time was 124.9 ± 19.9 minutes. The RA-CUSUM analysis identified an inflection point at case 55. Operative time decreased from 133.3 ± 21.7 minutes to 116.8 ± 13.7 minutes after this point ( P < .001). Prophylactic abdominal drainage was omitted in 58 patients (51.8%). Bile leakage occurred in 7 patients (6.2%) and was managed without reoperation. Spontaneous stent dislodgement was confirmed in 101 patients (90.2%). Retained CBD stones occurred in 4 patients (3.6%) and were successfully treated by endoscopic retrograde cholangiopancreatography-based endoscopic stone extraction. Conclusion: In selected patients, SIL-CBDE with a single-bend internal biliary stent appeared feasible and safe. This protocol may support temporary transpapillary decompression, spontaneous stent passage, and selective abdominal drain omission in enhanced recovery after surgery-oriented biliary surgery.


  • Open Access

    Management of rare biliary duct variants using a nasobiliary drainage tube and wire-guided navigation during laparoscopic cholecystectomy: a case report

    by Cheng Zhang, Yun-Sheng Suo, Sheng-Long Zhang, Ke Sun, Yang He, Guang-Kuo Li

    Biliary anatomical variation is an important risk factor for bile duct injury during laparoscopic cholecystectomy [1]. In the present case, we used a nasobiliary drainage tube and wire-guided navigation to identify a rare biliary variant and provide intraoperative guidance to reduce the risk of bile duct injury during laparoscopic cholecystectomy ([Video 1]). Video 1 Use of a nasobiliary drainage tube and wire-guided navigation to identify a rare biliary variant and provide intraoperative guidance to reduce the risk of bile duct injury during laparoscopic cholecystectomy. A 29-year-old woman was admitted with a 3-day history of upper abdominal pain and jaundice. Magnetic resonance cholangiopancreatography revealed that the cystic duct inserted into the right posterior sectoral duct (RPSD) and a suspected stone was located at the lower end of the common bile duct ([Fig. 1]). Endoscopic retrograde cholangiopancreatography confirmed the presence of an abnormal junction between the cystic duct and RPSD ([Fig. 2 a]), classified as type 4A according to the right hepatic duct variant classification by Huang et al. [2]. Attempts to selectively cannulate the RPSD using a sphincterotome and guidewire were unsuccessful. However, we successfully cannulated the RPSD using a nasobiliary drainage tube (nasal biliary drainage catheter, ENBD-7-LIGUORY-C; Cook, Limerick, Ireland) and wire-guided navigation, confirming the aberrant junction of the cystic duct with the RPSD ([Fig. 2 b]). During surgery, the surgeon injected indocyanine green through the nasobiliary catheter to identify the RPSD and avoid its injury ([Fig. 3]). Postoperative nasobiliary tube cholangiography revealed unobstructed flow in the RPSD ([Fig. 4]). Endoscopy_UCTN_Code_TTT_1AR_2AK Article published online: 15 June 2023 © 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

  • Open Access

    Identifying Potential Tumor Antigens and Antigens-Related Subtypes in Hepatocellular Carcinoma for mRNA Vaccine Development

    by Weiran Liao, Zhitian Shi, Haoren Tang, Tiangen Wu, Cheng Zhang, Yutao He, Renchao Zou, Lin Wang

    Background. The mRNA vaccine has become a promising platform for cancer therapy. Lots of studies have been focusing on discovering novel potent cancer-associated antigens to develop mRNA vaccines against cancers. Besides, immunotyping shows the immune status, and immune microenvironment of immunotyping is related with therapeutic reaction. However, potential antigens for mRNA vaccines and immunotyping of liver hepatocellular carcinoma (LIHC) remain far from being understood. Methods. In this study, we collected gene expression data and clinical information data from ICGC and TCGA databases. Using GEPIA2, we calculated differential expression genes and prognostic indices. We applied TIMER to calculate the correlation coefficient between immune infiltrating cells and each gene. Consensus cluster was used for immunotyping of LIHC. Results. We uncovered four most potential candidates including PES1, MCM3, PPM1G, and KPNA2, which were all related with antigen-presenting cell (APC) infiltration and poor survival in LIHC in two independent datasets. Furthermore, three immune-related subtypes (IS1-IS3) of LIHC were identified. All these results were validated in two independent datasets. Furthermore, we validated our results in vitro. Conclusions. The above candidates will be expected to be potential antigen genes for developing anti-LIHC mRNA vaccine, and furthermore, patients with IS2 and IS3 tumors are supposed to be appropriate for mRNA vaccine in LIHC.


  • Open Access

    The relationship among Girdin DNA methylation, its high expression, and immune infiltration in hepatocellular carcinoma: Clues from in silico analysis

    by Cheng Zhang, Yang Ke, Xuefen Lei, Xin Liu, Hai Li, Runjiao Shi, Lin Wang

    Objective: The aim of the present study was to explore the relationship among Girdin DNA methylation, its high expression, and immune infiltration in human hepatocellular carcinoma (HCC). Materials and methods: The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and International Cancer Genome Consortium (ICGC) databases were used to compare Girdin mRNA expression between HCC tissues and normal tissues, and determine the relationship between Girdin expression and HCC prognosis. TCGA database was also used to analyze the expression of Girdin and its methylation status, as well as the relationship between Girdin DNA methylation and HCC prognosis. The Tumor IMmune Estimation Resource (TIMER) database was used to explore the correlation between Girdin expression and HCC immune infiltration. Results: Girdin expression was elevated in HCC tissues compared with that in normal tissues. The degree of methylation at cg03188526, a CpG site in the Girdin gene body, was positively correlated with Girdin mRNA expression, while high Girdin expression and cg03188526 hypermethylation were both correlated with poor HCC prognosis. Additionally, HCC tissue with high Girdin expression exhibited abundant immune infiltration, and the high Girdin expression was associated with a worse prognosis in macrophage-enriched HCC specimens. Conclusion: Our findings indicated that Girdin likely functions as an oncogene in HCC and that hypermethylation at cg03188526 in the Girdin gene body may explain the high Girdin expression levels in HCC tissue. Furthermore, we report for the first time that the adverse effects of high Girdin expression in HCC patients may be partially mediated by tumor macrophage infiltration.